Form 4: Senti Biosciences Director Acquires Stock Options

Director James J. Collins acquires stock options in Senti Biosciences.

Summary

• On March 7, 2025, James J. Collins, a director of Senti Biosciences, Inc. acquired 43,900 stock options with an exercise price of $3.52.
• These options vest 100% on the first anniversary of the grant date, contingent upon continued service.
• The options expire on March 6, 2035.
• Following the transaction, Collins directly owns 43,900 derivative securities.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The acquisition of stock options by a director is generally viewed as a mildly positive signal.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This is a standard practice for incentivizing company directors and aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across the biotechnology industry.
• Companies like Amgen, Gilead, and Biogen routinely grant stock options to their directors as part of their compensation packages.
• The vesting schedules and exercise prices are typically structured to incentivize long-term value creation.

Stakeholder Impact

• The acquisition of stock options by a director can potentially impact shareholders by aligning the director's interests with the company's long-term success.

Key Dates